Press releases | WebDisclosure

Basculer en Français

10965	Companies
240137	Keywords
168910	Articles
129233	Press releases

Home
Press releases

PRESS RELEASE

published on 07/30/2026 at 23:01, 1 month 12 days ago

Pinetree Capital Announces Unaudited Financial Results for the Period Ended June 30, 2026 and Management Changes
Pinetree Capital Ltd. announces unaudited financial results for the three month period ended June 30, 2026, including a decrease in book value per share and management changes

Financial Results Pinetree Capital Ltd. Non-IFRS Measures Management Changes BVPS
PRESS RELEASE

published on 07/30/2026 at 23:00, 1 month 12 days ago

Eagle Plains Announces Approval of Warrant Expiry Extension
Eagle Plains Resources Ltd. receives TSX Venture Exchange approval to amend term of outstanding common share purchase warrants and extend expiry date. Company focuses on mineral projects in western Canada

Mineral Projects TSX Venture Exchange Western Canada Common Share Purchase Warrants Eagle Plains Resources
PRESS RELEASE

published on 07/30/2026 at 22:15, 1 month 12 days ago

Voting Rights and Shares Capital of the Company
Nanobiotix announces voting rights and shares capital update. Company listed on Euronext Paris and Nasdaq. Pioneering biotech firm with disruptive therapeutic approaches

Euronext Paris Voting Rights Nasdaq Shares Capital NANOBIOTIX
PRESS RELEASE

published on 07/30/2026 at 22:15, 1 month 12 days ago

INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Communiqué mensuel sur les droits de vote et d'actions de Nanobiotix, société de biotechnologie, cotée sur Euronext Paris et Nasdaq, avec plus de 30 familles de brevets en nanotechnologie

Euronext Paris Droits De Vote Biotechnologie Brevets NANOBIOTIX
PRESS RELEASE

published on 07/30/2026 at 22:12, 1 month 12 days ago

Michel Alkhalil, M.D., Announces Integrated Specialty Care Offerings at AAIRS Clinic and Troy Sleep Center
TROY, MI, July 30th, 2026, FinanceWire
PRESS RELEASE

published on 07/30/2026 at 22:05, 1 month 12 days ago

Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
Abivax announces positive pre-NDA interaction with FDA for Obefazimod, on track for NDA submission by end of 2026, reinforcing potential in treating ulcerative colitis

FDA Abivax Obefazimod Ulcerative Colitis NDA Submission
PRESS RELEASE

published on 07/30/2026 at 22:05, 1 month 12 days ago

Abivax annonce un retour positif de la FDA à l’issue de ses échanges pré-NDA concernant l’obéfazimod
Abivax annonce un retour positif de la FDA à l’issue de ses échanges pré-NDA concernant l’obéfazimod. La société se prépare à déposer sa première NDA d'ici fin 2026

FDA Abivax Obefazimod Rectocolite Hémorragique NDA
PRESS RELEASE

published on 07/30/2026 at 21:49, 1 month 12 days ago

Inside Information / News release on accounts, results
Aliko Scientific (Ikonisys SA) reports 52.6% increase in total revenue to €1.64 million and 32.9% improvement in EBITDA for 2025. Developments include US patent for ACTA, launch of Urine24, and agreement with Menarini Diagnostics

Financial Results Revenue Increase EBITDA Improvement Oncology Diagnostics ALIKO SCIENTIFIC
PRESS RELEASE

published on 07/30/2026 at 21:49, 1 month 12 days ago

Informations privilégiées / Communiqué sur comptes, résultats
Ikonisys SA publie ses résultats financiers annuels 2025. Amélioration de 32,9% de l'EBITDA à -1,14 M€. Développement de la plateforme oncologique avec brevet ACTA, Urine24 et accord Menarini Diagnostics

Résultats Financiers EBITDA Ikonisys SA Développements Plateforme Oncologique
PRESS RELEASE

published on 07/30/2026 at 21:41, 1 month 12 days ago

Digita Global Marketing Marks a Decade of Growth and Innovation Across the Caribbean
KINGSTON, Jamaica, July 30th, 2026, FinanceWire

Accesswire

Published on 09/12/2026 at 02:35, 11 hours 49 minutes ago

Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 15 hours 24 minutes ago

Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 16 hours 19 minutes ago

Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 59 minutes ago

Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 21 hours 24 minutes ago

Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors

View all ACCESSWIRE

EQS Group

Published on 09/12/2026 at 07:30, 6 hours 54 minutes ago

NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 16 hours 9 minutes ago

Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 16 hours 14 minutes ago

Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 40 minutes ago

DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 20 hours 9 minutes ago

CGTN: How BRICS creates new opportunities for Global South development

Les Echos

Published on 09/11/2026 at 07:00, 1 day 7 hours ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 1 day 7 hours ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 1 day 7 hours ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 7 hours ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE